<!doctype html><html lang=cn><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>依洛尤单抗——极高危ASCVD患者的新希望 | 极客快訊</title><meta property="og:title" content="依洛尤单抗——极高危ASCVD患者的新希望 - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="cn"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/153198987189420260f547c"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%a6/f4f6ea93.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%a6/f4f6ea93.html><meta property="article:published_time" content="2020-11-14T20:50:51+08:00"><meta property="article:modified_time" content="2020-11-14T20:50:51+08:00"><meta name=Keywords content><meta name=description content="依洛尤单抗——极高危ASCVD患者的新希望"><meta name=author content="极客快訊"><meta property="og:url" content="/cn/%E7%A7%91%E5%AD%A6/f4f6ea93.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快讯 Geek Bank</a></h1><p class=description>为你带来最全的科技知识 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>依洛尤单抗——极高危ASCVD患者的新希望</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=cn/categories/%E7%A7%91%E5%AD%A6.html>科学</a></span></div><div class=post-content><img alt=依洛尤单抗——极高危ASCVD患者的新希望 onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/153198987189420260f547c><p>◆</p><p>依洛尤单抗是国内<strong>唯一获批</strong>的前蛋白转化酶枯草溶菌素/Kexin 9型（PCSK9）抑制剂，属于心血管慢病领域<strong>开创性的靶向降脂药物</strong></p><p>◆</p><p>依洛尤单抗可以解决现有降脂药物无法满足的<strong>极高危</strong>动脉粥样硬化性心血管疾病（<strong>ASCVD</strong>）患者的临床需求，复合主要心血管事件风险降低15%<sup>2</sup></p><p>◆</p><p>依洛尤单抗可以为<strong>罕见病</strong><strong>纯合子型家族性高胆固醇血症</strong>（<strong>HoFH</strong>）患者提供有效治疗方案</p><p>◆</p><p>依洛尤单抗是国家医保目录明确优先考虑的<strong>慢性病及罕见病用药</strong></p><p>现有药物治疗下，极高危血脂异常患者LDL-C达标率仅为23.9%<sup>1</sup>，未满足临床需求巨大。依洛尤单抗在他汀基础上进一步降低LDL-C水平平均达59%<sup>2</sup>，中国人群的LDL-C水平降幅更为显著高达73.0%~78.9%，92.3-98.4%接受依洛尤单抗治疗的患者达到指南推荐目标值（&lt;70 mg/dl）<sup>3</sup>。安全耐受性良好，每两周注射一次140 mg或每月注射一次420 mg，使用简便。</p><p><strong>中国获批适应症：</strong></p><p>1. 心血管事件的预防: 在已有动脉粥样硬化性心血管疾病的成人患者中，降低心肌梗死、卒中以及冠脉血运重建的风险。通过：与最大耐受剂量的他汀类药物联合用药，伴随或不伴随其他降脂疗法，或者在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用药。</p><p>2. 用于成人或12岁以上青少年的纯合子型家族性高胆固醇血症。可与饮食疗法和其他降低密度脂蛋白（LDL）治疗（例如他汀类药物、依折麦布、LDL分离术）合用，用于患有HoFH且需要进一步降低低密度脂蛋白胆固醇（LDL-C）的患者。</p><p>参考文献：</p><p>1. Gitt AK, et al. Atherosclerosis (2016), doi: 10.1016/j.atherosclerosis.2016.09.004.</p><p>2. Sabatine MS, et al. N Engl J Med 2017;376:1713-22.</p><p>3. 依洛尤单抗注射液说明书</p><p>（来源：《国际循环》编辑部）</p><p>版</p><p>权</p><p>声</p><p>明</p><p>版权属《国际循环》所有。欢迎个人转发分享。其他任何媒体、网站如需转载或引用本网版权所有之内容须在醒目位置处注明“转自《国际循环》”</p><p>我怎么这么好看</p></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>'依洛','单抗','极高危'</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=application/javascript>var doNotTrack=false;if(!doNotTrack){window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;ga('create','UA-146415161-2','auto');ga('send','pageview');}</script><script async src=https://www.google-analytics.com/analytics.js></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>